Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Molecular Partners Ag ADR (NQ: MOLN )

5.285 -0.135 (-2.49%)
Streaming Delayed Price Updated: 3:33 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Molecular Partners Ag ADR

< Previous 1 2 3 4 5 6 7 Next >
Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy
From Molecular Partners
Via GlobeNewswire
Molecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACR
From Molecular Partners
Via GlobeNewswire
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
From Molecular Partners
Via GlobeNewswire
Molecular Partners Publishes Invitation to Annual General Meeting 2023
From Molecular Partners
Via GlobeNewswire
Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022
From Molecular Partners
Via GlobeNewswire
Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Ambrx Pharmaceuticals, Inc. could see positive earnings next year. And while share value could go down, analysts thin rate AMAM a Moderate Buy 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference
From Molecular Partners
Via GlobeNewswire
Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform
From Molecular Partners
Via GlobeNewswire
Molecular Partners to Present at SVB Leerink Global Healthcare Conference
From Molecular Partners
Via GlobeNewswire
Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid Leukemia
From Molecular Partners
Via GlobeNewswire
Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference
From Molecular Partners
Via GlobeNewswire
Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML
From Molecular Partners
Via GlobeNewswire
Molecular Partners Announces Acceptance of Oral Presentation at the Annual American Society of Hematology Meeting
- Company will also host a reception with Key Opinion Leaders in New Orleans - 
From Molecular Partners
Via GlobeNewswire
Molecular Partners Announces Upcoming Participation in Investor and Scientific Conferences
From Molecular Partners
Via GlobeNewswire
Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End
From Molecular Partners
Via GlobeNewswire
Molecular Partners Announces Planned Departure of Chief Financial Officer
From Molecular Partners
Via GlobeNewswire
Molecular Partners AG (NASDAQ:MOLN) Long Term Investor Alert: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 10/26/2022 -- An investigation was announced for current long-term investors in shares of Molecular Partners AG (NASDAQ:MOLN) concerning potential breaches of fiduciary... 
Via SBWire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers NeuroMetrix (NASDAQ:NURO) shares increased by 23.0% to $3.48 during Monday's pre-market session. The company's market cap stands at $24.8 million. 
Via Benzinga
NASDAQ:MOLN Investor Notice: Deadline Coming Up on September 12, 2022 in Lawsuit Against Molecular Partners AG
San Diego, CA -- (SBWIRE) -- 09/12/2022 -- A deadline is coming up on September 12, 2022 in the lawsuit filed for certain investors of Molecular Partners AG (NASDAQ:MOLN). 
Via SBWire
Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Molecular Partners AG (MOLN) Investors of Class Action and Last Few Hours to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
FINAL INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Molecular Partners AG with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
MOLN DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Molecular Partners AG Investors With Losses to Secure Counsel Before Important September 12 Deadline in Securities Class Action - MOLN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
Exposures COVID-19 Financial Legal
MOLECULAR PARTNERS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Molecular Partners AG and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Molecular Partners AG Investors to Secure Counsel Before Important Deadline in Securities Class Action - MOLN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
Exposures COVID-19 Financial Legal
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022
Upgrades 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 250 stocks hit new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
  
Via Benzinga
SVB Leerink Slashes Price Target On This Stock By Over 73%, Plus This Analyst Predicts $56 For Toll Brothers
Citigroup raised the price target for MacroGenics, Inc. (NASDAQ: MGNX) from $13 to $16. MacroGenics shares rose 4.8% to $3.90 in pre-market trading. 
Via Benzinga
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Molecular Partners AG Investors to Secure Counsel Before Important Deadline in Securities Class Action - MOLN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
Exposures COVID-19 Financial Legal
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.